{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:45:59Z","timestamp":1791895559126,"version":"4.3.4"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Rising levels of parathyroid hormone (PTH) are common in patients with chronic kidney disease (CKD) not on dialysis and are associated with an elevated risk of morbidity (including progression to dialysis) and mortality. However, there are several challenges for the clinical management of secondary hyperparathyroidism (SHPT) in this population. While no recognised target level for PTH currently exists, it is accepted that patients with non-dialysis CKD should receive early and regular monitoring of PTH from CKD stage G3a. However, studies indicate that adherence to monitoring recommendations in non-dialysis CKD may be suboptimal. SHPT is linked to vitamin D [25(OH)D] insufficiency in non-dialysis CKD, and correction of low 25(OH)D levels is a recognised management approach. A second challenge is that target 25(OH)D levels are unclear in this population, with recent evidence suggesting that the level of 25(OH)D above which suppression of PTH progressively diminishes may be considerably higher than that recommended for the general population. Few therapeutic agents are licensed for use in non-dialysis CKD patients with SHPT and optimal management remains controversial. Novel approaches include the development of calcifediol in an extended-release formulation, which has been shown to increase 25(OH)D gradually and provide a physiologically-regulated increase in 1,25(OH)\n                      <jats:sub>2<\/jats:sub>\n                      D that can reliably lower PTH in CKD stage G3\u2013G4 without clinically meaningful increases in serum calcium and phosphate levels. Additional studies would be beneficial to assess the comparative effects of available treatments, and to more clearly elucidate the overall benefits of lowering PTH in non-dialysis CKD, particularly in terms of hard clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-021-01082-2","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:03:16Z","timestamp":1624618996000},"page":"1405-1418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease"],"prefix":"10.1093","volume":"34","author":[{"given":"Markus","family":"Ketteler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Amb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"1082_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov B, Purcell CA, Levey AS et al (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 395:709\u2013733. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3","journal-title":"The Lancet"},{"key":"1082_CR2","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00198-019-05033-3","volume":"30","author":"S Geng","year":"2019","unstructured":"Geng S, Kuang Z, Peissig PL et al (2019) Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporos Int 30:2019\u20132025. https:\/\/doi.org\/10.1007\/s00198-019-05033-3","journal-title":"Osteoporos Int"},{"key":"1082_CR3","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1185\/03007990802437943","volume":"24","author":"GT Schumock","year":"2008","unstructured":"Schumock GT, Andress D, Marx SE et al (2008) Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients. Curr Med Res Opin 24:3037\u20133048. https:\/\/doi.org\/10.1185\/03007990802437943","journal-title":"Curr Med Res Opin"},{"key":"1082_CR4","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A et al (2018) Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. The Lancet 392:2052\u20132090. https:\/\/doi.org\/10.1016\/S0140-6736(18)31694-5","journal-title":"The Lancet"},{"key":"1082_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.ajkd.2019.07.02275:10","volume":"75","author":"T Isakova","year":"2020","unstructured":"Isakova T, Cai X, Lee J et al (2020) Longitudinal evolution of markers of mineral metabolism in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 75:235\u2013244. https:\/\/doi.org\/10.1053\/j.ajkd.2019.07.02275:10","journal-title":"Am J Kidney Dis"},{"key":"1082_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913\u2013921. https:\/\/doi.org\/10.2215\/CJN.06040710","journal-title":"Clin J Am Soc Nephrol"},{"key":"1082_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl"},{"key":"1082_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336. https:\/\/doi.org\/10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int"},{"key":"1082_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ckj\/sfy061","volume":"12","author":"PA Ure\u00f1a-Torres","year":"2019","unstructured":"Ure\u00f1a-Torres PA, Vervloet M, Mazzaferro S et al (2019) Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. Clin Kidney J 12:269\u2013280. https:\/\/doi.org\/10.1093\/ckj\/sfy061","journal-title":"Clin Kidney J"},{"key":"1082_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jbmr.3893","volume":"35","author":"Y Lee","year":"2020","unstructured":"Lee Y, Okuda Y, Sy J et al (2020) Association of mineral bone disorder with decline in residual kidney function in incident hemodialysis patients. J Bone Miner Res 35:317\u2013325. https:\/\/doi.org\/10.1002\/jbmr.3893","journal-title":"J Bone Miner Res"},{"key":"1082_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa143.P0878","author":"M Bermudez-Lopez","year":"2020","unstructured":"Bermudez-Lopez M, Forn\u00e9 C, Cambray S et al (2020) Independent effects of secondary hyperparathyroidism on chronic kidney disease progression and cardiovascular events in the NEFRONA cohort. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa143.P0878","journal-title":"Nephrol Dial Transplant"},{"key":"1082_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000497477","volume":"49","author":"NS Roetker","year":"2019","unstructured":"Roetker NS, Peng Y, Ashfaq A et al (2019) Adherence to Kidney Disease: improving Global Outcomes mineral and bone guidelines for monitoring biochemical parameters. Am J Nephrol 49:225\u2013232. https:\/\/doi.org\/10.1159\/000497477","journal-title":"Am J Nephrol"},{"key":"1082_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/ASN.2009121293","volume":"21","author":"M Wolf","year":"2010","unstructured":"Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427\u20131435. https:\/\/doi.org\/10.1681\/ASN.2009121293","journal-title":"J Am Soc Nephrol"},{"key":"1082_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31\u201338. https:\/\/doi.org\/10.1038\/sj.ki.5002009","journal-title":"Kidney Int"},{"key":"1082_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1253\/circj.CJ-19-1201","volume":"84","author":"H Arase","year":"2020","unstructured":"Arase H, Yamada S, Tanaka S et al (2020) Association between plasma intact parathyroid hormone levels and the prevalence of atrial fibrillation in patients with chronic kidney disease\u2014the Fukuoka Kidney Disease Registry study. Circ J 84:1105\u20131111. https:\/\/doi.org\/10.1253\/circj.CJ-19-1201","journal-title":"Circ J"},{"key":"1082_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfx059","volume":"33","author":"P-A Westerberg","year":"2018","unstructured":"Westerberg P-A, Sterner G, Ljunggren \u00d6 et al (2018) High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3\u20134: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant 33:466\u2013471. https:\/\/doi.org\/10.1093\/ndt\/gfx059","journal-title":"Nephrol Dial Transplant"},{"key":"1082_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa142.P0891","author":"J Gunnarsson","year":"2020","unstructured":"Gunnarsson J, Lauppe R, Kaiser E et al (2020) Meta-analysis of nutritional vitamin D for the treatment of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa142.P0891","journal-title":"Nephrol Dial Transplant"},{"key":"1082_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P et al (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in Stages 3 and 4 CKD. Am J Kidney Dis 47:263\u2013276. https:\/\/doi.org\/10.1053\/j.ajkd.2005.10.007","journal-title":"Am J Kidney Dis"},{"key":"1082_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000450766","volume":"44","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Crawford PW, Melnick JZ et al (2016) Use of extended-release calcifediol to treat secondary hyperparathyroidism in Stages 3 and 4 chronic kidney disease. Am J Nephrol 44:316\u2013325. https:\/\/doi.org\/10.1159\/000450766","journal-title":"Am J Nephrol"},{"key":"1082_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/gfaa195","volume":"36","author":"N Tabibzadeh","year":"2020","unstructured":"Tabibzadeh N, Karaboyas A, Robinson BM et al (2020) The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrol Dial Transpl 36:160\u2013169. https:\/\/doi.org\/10.1093\/ndt\/gfaa195","journal-title":"Nephrol Dial Transpl"},{"key":"1082_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/01.tp.0000228923.75739.88","volume":"82","author":"JI Roodnat","year":"2006","unstructured":"Roodnat JI, van Gurp EAFJ, Mulder PGH et al (2006) High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation 82:362\u2013367. https:\/\/doi.org\/10.1097\/01.tp.0000228923.75739.88","journal-title":"Transplantation"},{"key":"1082_CR22","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/j.1600-6143.2005.00938.x","volume":"5","author":"W Gwinner","year":"2005","unstructured":"Gwinner W, Suppa S, Mengel M et al (2005) Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 5:1934\u20131941. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.00938.x","journal-title":"Am J Transplant"},{"key":"1082_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1590\/S1807-59322011000300012","volume":"66","author":"GF Ferreira","year":"2011","unstructured":"Ferreira GF, Montegegro FL, Machado DJ et al (2011) Parathyroidectomy after kidney transplantation: short- and long-term impact on renal function. Clinics 66:431\u2013435. https:\/\/doi.org\/10.1590\/S1807-59322011000300012","journal-title":"Clinics"},{"key":"1082_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2215\/CJN.10360917","volume":"13","author":"E Ku","year":"2018","unstructured":"Ku E, Johansen KL, McCulloch CE (2018) Time-centered approach to understanding risk factors for the progression of CKD. Clin J Am Soc Nephrol 13:693\u2013701. https:\/\/doi.org\/10.2215\/CJN.10360917","journal-title":"Clin J Am Soc Nephrol"},{"key":"1082_CR25","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2215\/CJN.103909171","volume":"13","author":"WL Lau","year":"2018","unstructured":"Lau WL, Obi Y, Kalantar-Zadeh K (2018) Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol 13:952\u2013996. https:\/\/doi.org\/10.2215\/CJN.103909171","journal-title":"Clin J Am Soc Nephrol"},{"key":"1082_CR26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ekir.2020.12.036","volume":"6","author":"JB Wetmore","year":"2021","unstructured":"Wetmore JB, Ji Y, Ashfaq A et al (2021) Testing patterns for CKD-MBD abnormalities in a sample US population. Kidney Int Rep 6:1141\u20131150. https:\/\/doi.org\/10.1016\/j.ekir.2020.12.036","journal-title":"Kidney Int Rep"},{"key":"1082_CR27","doi-asserted-by":"publisher","first-page":"115058","DOI":"10.1016\/j.bone.2019.115058","volume":"129","author":"S Liabeuf","year":"2019","unstructured":"Liabeuf S, McCullough K, Young EW et al (2019) International variation in the management of mineral bone disorder in patients with chronic kidney disease: results from CKDopps. Bone 129:115058. https:\/\/doi.org\/10.1016\/j.bone.2019.115058","journal-title":"Bone"},{"key":"1082_CR28","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:1911\u20131930. https:\/\/doi.org\/10.1210\/jc.2011-0385","journal-title":"J Clin Endocrinol Metab"},{"key":"1082_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrneph.2009.185","volume":"5","author":"CRC Doorenbos","year":"2009","unstructured":"Doorenbos CRC, van den Born J, Navis G, de Borst MH (2009) Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 5:691\u2013700. https:\/\/doi.org\/10.1038\/nrneph.2009.185","journal-title":"Nat Rev Nephrol"},{"key":"1082_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ki.2008.501","volume":"75","author":"P Ravani","year":"2009","unstructured":"Ravani P, Malberti F, Tripepi G et al (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:88\u201395. https:\/\/doi.org\/10.1038\/ki.2008.501","journal-title":"Kidney Int"},{"key":"1082_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx147.SP368","author":"F Tentori","year":"2017","unstructured":"Tentori F, Tu C, Zepel L et al (2017) Treatments of mineral and bone disorder may be under-utilized in CKD patients. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfx147.SP368","journal-title":"Nephrol Dial Transplant"},{"key":"1082_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1210\/clinem\/dgz282","volume":"105","author":"R Bouillon","year":"2020","unstructured":"Bouillon R (2020) Safety of high-dose vitamin D supplementation. J Clin Endocrinol Metab 105:1290\u20131291. https:\/\/doi.org\/10.1210\/clinem\/dgz282","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 113","key":"1082_CR33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD). Kidney Int 76(suppl 113):S1\u2013S130. https:\/\/doi.org\/10.1038\/ki.2009.188","journal-title":"Kidney Int"},{"key":"1082_CR34","unstructured":"Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al, editors (2011) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK56070\/. Accessed 20 May 2021"},{"key":"1082_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.beem.2011.05.005","volume":"25","author":"A Dusso","year":"2011","unstructured":"Dusso A, Gonz\u00e1lez EA, Martin KJ (2011) Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab 25:647\u2013655. https:\/\/doi.org\/10.1016\/j.beem.2011.05.005","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1082_CR36","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1210\/er.2018-00126","volume":"40","author":"R Bouillon","year":"2019","unstructured":"Bouillon R, Marcocci C, Carmeliet G et al (2019) Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 40:1109\u20131151. https:\/\/doi.org\/10.1210\/er.2018-00126","journal-title":"Endocr Rev"},{"key":"1082_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bbacli.2015.03.004","volume":"3","author":"M Pasquali","year":"2015","unstructured":"Pasquali M, Tartaglione L, Rotondi S et al (2015) Calcitriol\/calcifediol ratio: an indicator of vitamin D hydroxylation efficiency? BBA Clin 3:251\u2013256. https:\/\/doi.org\/10.1016\/j.bbacli.2015.03.004","journal-title":"BBA Clin"},{"key":"1082_CR38","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.5301\/jn.5000102","volume":"25","author":"F Citterio","year":"2012","unstructured":"Citterio F, Mazzaferro S, Pasquali M et al (2012) Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: a role for FGF23. J Nephrol 25:1108\u20131118. https:\/\/doi.org\/10.5301\/jn.5000102","journal-title":"J Nephrol"},{"key":"1082_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MNH.0b013e3283477a7b","volume":"20","author":"M Petkovich","year":"2011","unstructured":"Petkovich M, Jones G (2011) CYP24A1 and kidney disease. Curr Opin Nephrol Hypertens 20:337\u2013344. https:\/\/doi.org\/10.1097\/MNH.0b013e3283477a7b","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1082_CR40","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1080\/14656566.2019.1663826","volume":"20","author":"M Cozzolino","year":"2019","unstructured":"Cozzolino M, Ketteler M (2019) Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). Expert Opin Pharmacother 20:2081\u20132093. https:\/\/doi.org\/10.1080\/14656566.2019.1663826","journal-title":"Expert Opin Pharmacother"},{"key":"1082_CR41","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1210\/jc.2010-2230","volume":"96","author":"RP Heaney","year":"2011","unstructured":"Heaney RP, Recker RR, Grote J et al (2011) Vitamin D3 is more potent than vitamin D2 in humans. J Clin Endocrinol Metab 96:E447\u2013E452. https:\/\/doi.org\/10.1210\/jc.2010-2230","journal-title":"J Clin Endocrinol Metab"},{"key":"1082_CR42","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1210\/jc.2014-1714","volume":"99","author":"KS Jones","year":"2014","unstructured":"Jones KS, Assar S, Harnpanich D et al (2014) 25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. J Clin Endocrinol Metab 99:3373\u20133381. https:\/\/doi.org\/10.1210\/jc.2014-1714","journal-title":"J Clin Endocrinol Metab"},{"key":"1082_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266\u2013281. https:\/\/doi.org\/10.1056\/NEJMra070553","journal-title":"N Engl J Med"},{"key":"1082_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.03940510","volume":"6","author":"P Kandula","year":"2011","unstructured":"Kandula P, Dobre M, Schold JD et al (2011) Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 6:50\u201362. https:\/\/doi.org\/10.2215\/CJN.03940510","journal-title":"Clin J Am Soc Nephrol"},{"key":"1082_CR45","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/ndt\/gfw080","volume":"31","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Georgianos PI (2016) Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 31:706\u2013713. https:\/\/doi.org\/10.1093\/ndt\/gfw080","journal-title":"Nephrol Dial Transplant"},{"key":"1082_CR46","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/ndt\/gfaa172","volume":"36","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Georgianos PI (2021) Erratum: Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 36:566\u2013567. https:\/\/doi.org\/10.1093\/ndt\/gfaa172","journal-title":"Nephrol Dial Transplant"},{"key":"1082_CR47","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.2215\/CJN.00530117","volume":"12","author":"Z Batacchi","year":"2017","unstructured":"Batacchi Z, Robinson-Cohen C, Hoofnagle AN et al (2017) Effects of vitamin D2 supplementation on vitamin D3 metabolism in health and CKD. Clin J Am Soc Nephrol 12:1498\u20131506. https:\/\/doi.org\/10.2215\/CJN.00530117","journal-title":"Clin J Am Soc Nephrol"},{"key":"1082_CR48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/jbmr.3686","volume":"34","author":"JD Roizen","year":"2019","unstructured":"Roizen JD, Long C, Casella A et al (2019) Obesity decreases hepatic 25-hydroxylase activity causing low serum 25-hydroxyvitamin D. J Bone Miner Res 34:1068\u20131073. https:\/\/doi.org\/10.1002\/jbmr.3686","journal-title":"J Bone Miner Res"},{"key":"1082_CR49","first-page":"102","volume":"2","author":"PJ Bordier","year":"1975","unstructured":"Bordier PJ (1975) Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. Kidney Int Suppl 2:102\u2013112","journal-title":"Kidney Int Suppl"},{"key":"1082_CR50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/978-1-4613-4217-5","volume-title":"Phosphate metabolism","author":"JM Letteri","year":"1977","unstructured":"Letteri JM, Kleinman LM, Ellis KN et al (1977) Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure. In: Massry SG, Ritz E (eds) Phosphate metabolism. Springer US, New York, pp 591\u2013601. https:\/\/doi.org\/10.1007\/978-1-4613-4217-5"},{"key":"1082_CR51","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00198-018-4520-y","volume":"29","author":"JM Quesada-Gomez","year":"2018","unstructured":"Quesada-Gomez JM, Bouillon R (2018) Is calcifediol better than cholecalciferol for vitamin D supplementation? Osteoporos Int 29:1697\u20131711. https:\/\/doi.org\/10.1007\/s00198-018-4520-y","journal-title":"Osteoporos Int"},{"key":"1082_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","volume":"148","author":"M Petkovich","year":"2015","unstructured":"Petkovich M, Melnick J, White J et al (2015) Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation. J Steroid Biochem Mol Biol 148:283\u2013289. https:\/\/doi.org\/10.1016\/j.jsbmb.2014.11.022","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1082_CR53","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.10661013","volume":"9","author":"DW Coyne","year":"2014","unstructured":"Coyne DW, Goldberg S, Faber M et al (2014) A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in Stages 3\u20134 CKD. Clin J Am Soc Nephrol 9:1620\u20131626. https:\/\/doi.org\/10.2215\/CJN.10661013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 3","key":"1082_CR54","doi-asserted-by":"publisher","first-page":"s913","DOI":"10.1016\/j.jval.2019.09.2686","volume":"22","author":"P Csomor","year":"2019","unstructured":"Csomor P, Dubois E, Bernard L (2019) Active vitamin D therapy increases the risk of hypercalcemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Value Health: Urinary\/Kidney Dis Clin Outcomes 22(suppl 3):s913. https:\/\/doi.org\/10.1016\/j.jval.2019.09.2686","journal-title":"Value Health: Urinary\/Kidney Dis Clin Outcomes"},{"key":"1082_CR55","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.070305","volume":"22","author":"A Card\u00fas","year":"2007","unstructured":"Card\u00fas A, Panizo S, Parisi E et al (2007) Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22:860\u2013866. https:\/\/doi.org\/10.1359\/jbmr.070305","journal-title":"J Bone Miner Res"},{"key":"1082_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.605","volume":"8","author":"BA Svajger","year":"2020","unstructured":"Svajger BA, Pruss CM, Laverty KJ et al (2020) PTH suppression by calcitriol does not predict off-target actions in experimental CKD. Pharmacol Res Perspect 8:1\u201312. https:\/\/doi.org\/10.1002\/prp2.605","journal-title":"Pharmacol Res Perspect"},{"key":"1082_CR57","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674\u2013684. https:\/\/doi.org\/10.1001\/jama.2012.120","journal-title":"JAMA"},{"key":"1082_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY-M Wang","year":"2014","unstructured":"Wang AY-M, Fang F, Chan J et al (2014) Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial. J Am Soc Nephrol 25:175\u2013186. https:\/\/doi.org\/10.1681\/ASN.2013010103","journal-title":"J Am Soc Nephrol"},{"key":"1082_CR59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17446651.2017.1347501","volume":"12","author":"SM Sprague","year":"2017","unstructured":"Sprague SM, Strugnell SA, Bishop CW (2017) Extended-release calcifediol for secondary hyperparathyroidism in stage 3\u20134 chronic kidney disease. Expert Rev Endocrinol Metab 12:289\u2013301. https:\/\/doi.org\/10.1080\/17446651.2017.1347501","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1082_CR60","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000499187","volume":"49","author":"SA Strugnell","year":"2019","unstructured":"Strugnell SA, Sprague SM, Ashfaq A et al (2019) Rationale for raising current clinical practice guideline target for serum 25-Hydroxyvitamin D in chronic kidney disease. Am J Nephrol 49:284\u2013293. https:\/\/doi.org\/10.1159\/000499187","journal-title":"Am J Nephrol"},{"key":"1082_CR61","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1053\/j.ajkd.2020.02.112","volume":"75","author":"G Fadda","year":"2020","unstructured":"Fadda G, Germain MJ, Broumand V et al (2020) Real-world assessment: clinical effectiveness and safety of extended-release calcifediol. Am J Kidney Dis 75:567. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.112","journal-title":"Am J Kidney Dis"},{"key":"1082_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa142.P0901","author":"MJ Germain","year":"2020","unstructured":"Germain MJ, Paul S, Fadda G et al (2020) Real-world assessment: clinical effectiveness and safety of ERC and vitamin D therapies in ND-CKD patients. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa142.P0901","journal-title":"Nephrol Dial Transplant"},{"key":"1082_CR63","unstructured":"Amgen Europe BV. Parsabiv (etelcalcetide) Summary of Product Characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/parsabiv-epar-product-information_en.pdf. Accessed 20 May 2021"},{"key":"1082_CR64","unstructured":"Amgen Europe BV. Mimpara (cinacalcet) Summary of Product Characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mimpara-epar-product-information_en.pdf. Accessed 20 May 2021"},{"key":"1082_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","volume":"53","author":"M Chonchol","year":"2009","unstructured":"Chonchol M, Locatelli F, Abboud HE et al (2009) A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53:197\u2013207. https:\/\/doi.org\/10.1053\/j.ajkd.2008.09.021","journal-title":"Am J Kidney Dis"},{"key":"1082_CR66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/ckj\/sfx086","volume":"11","author":"CTS Lim","year":"2018","unstructured":"Lim CTS, Kalaiselvam T, Kitan N, Goh BL (2018) Clinical course after parathyroidectomy in adults with end-stage renal disease on maintenance dialysis. Clin Kidney J 11:265\u2013269. https:\/\/doi.org\/10.1093\/ckj\/sfx086","journal-title":"Clin Kidney J"},{"key":"1082_CR67","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/ckj\/sfz187","volume":"13","author":"J Bover","year":"2020","unstructured":"Bover J, Urena-Torres P, Mateu S, DaSilva I (2020) Evidence in chronic kidney disease\u2013mineral and bone disorder guidelines: is it time to treat or time to wait? Clin Kidney J 13:513\u2013521. https:\/\/doi.org\/10.1093\/ckj\/sfz187","journal-title":"Clin Kidney J"},{"key":"1082_CR68","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.12.024","author":"M Pazianas","year":"2021","unstructured":"Pazianas M, Miller PD (2021) Osteoporosis and chronic kidney disease\u2013mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis. https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.024","journal-title":"Am J Kidney Dis"},{"key":"1082_CR69","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cca.2019.11.012","volume":"501","author":"A Nizet","year":"2020","unstructured":"Nizet A (2020) Bone alkaline phosphatase: an important biomarker in chronic kidney disease\u2014mineral and bone disorder. Clin Chim Acta 501:198\u2013206. https:\/\/doi.org\/10.1016\/j.cca.2019.11.012","journal-title":"Clin Chim Acta"},{"key":"1082_CR70","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cunningham J et al (2017) Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 317:146\u2013155. https:\/\/doi.org\/10.1001\/jama.2016.19456","journal-title":"JAMA"},{"key":"1082_CR71","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G et al (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800\u2013807. https:\/\/doi.org\/10.1681\/ASN.2004060512","journal-title":"J Am Soc Nephrol"},{"key":"1082_CR72","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1681\/ASN.2012030240","volume":"23","author":"A Pasch","year":"2012","unstructured":"Pasch A, Farese S, Gr\u00e4ber S et al (2012) Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 23:1744\u20131752. https:\/\/doi.org\/10.1681\/ASN.2012030240","journal-title":"J Am Soc Nephrol"},{"key":"1082_CR73","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jacbts.2020.02.002","volume":"5","author":"AJ Nelson","year":"2020","unstructured":"Nelson AJ, Raggi P, Wolf M et al (2020) Targeting vascular calcification in chronic kidney disease. JACC Basic Transl Sci 5:398\u2013412. https:\/\/doi.org\/10.1016\/j.jacbts.2020.02.002","journal-title":"JACC Basic Transl Sci"},{"key":"1082_CR74","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/toxins12030181","volume":"12","author":"A Himmelsbach","year":"2020","unstructured":"Himmelsbach A (2020) Cardiovascular calcification in chronic kidney disease\u2013therapeutic opportunities. Toxins 12:181. https:\/\/doi.org\/10.3390\/toxins12030181","journal-title":"Toxins"},{"key":"1082_CR75","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2215\/CJN.04710419","volume":"14","author":"JD Bundy","year":"2019","unstructured":"Bundy JD, Cai X, Mehta RC et al (2019) Serum calcification propensity and clinical events in CKD. Clin J Am Soc Nephrol 14:1562\u20131571. https:\/\/doi.org\/10.2215\/CJN.04710419","journal-title":"Clin J Am Soc Nephrol"},{"key":"1082_CR76","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2215\/CJN.04720416","volume":"12","author":"A Pasch","year":"2017","unstructured":"Pasch A, Block GA, Bachtler M et al (2017) Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE Trial. Clin J Am Soc Nephrol 12:315\u2013322. https:\/\/doi.org\/10.2215\/CJN.04720416","journal-title":"Clin J Am Soc Nephrol"},{"key":"1082_CR77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40620-015-0186-0","volume":"29","author":"JL Ennis","year":"2016","unstructured":"Ennis JL, Worcester EM, Coe FL, Sprague SM (2016) Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol 29:63\u201370. https:\/\/doi.org\/10.1007\/s40620-015-0186-0","journal-title":"J Nephrol"},{"key":"1082_CR78","unstructured":"Courbebaisse M, Colas S, Sberro-Soussan R, et al (2019) Non-skeletal and skeletal effects of high doses versus minimum recommended intake of vitamin D3 in renal transplant recipients in a prospective, multicenter, double-blind, randomized study. Abstract presented at ERA-EDTA Congress, Budapest. http:\/\/mediatheque.cyim.com\/mediatheque\/media.aspx?mediaId=70760&channel=60398. Accessed 20 May 2021"},{"key":"1082_CR79","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2018.06.031","volume":"72","author":"ML Melamed","year":"2018","unstructured":"Melamed ML, Chonchol M, Guti\u00e9rrez OM et al (2018) The role of Vitamin D in CKD Stages 3 to 4: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis 72:834\u2013845. https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.031","journal-title":"Am J Kidney Dis"},{"key":"1082_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11154-019-09532-w","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Adler RA, Binkley N et al (2020) Consensus statement from 2nd International Conference on Controversies in Vitamin D. Rev Endocr Metab Disord 21:89\u2013116. https:\/\/doi.org\/10.1007\/s11154-019-09532-w","journal-title":"Rev Endocr Metab Disord"},{"key":"1082_CR81","doi-asserted-by":"publisher","first-page":"105562","DOI":"10.1016\/j.jsbmb.2019.105562","volume":"198","author":"R Scragg","year":"2020","unstructured":"Scragg R (2020) The vitamin D assessment (ViDA) study\u2014design and main findings. J Steroid Biochem Mol Biol 198:105562. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105562","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1082_CR82","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/jbmr.3958","volume":"35","author":"MS LeBoff","year":"2020","unstructured":"LeBoff MS, Chou SH, Murata EM et al (2020) Effects of supplemental vitamin D on bone health outcomes in women and men in the VITamin D and omegA-3 triaL (VITAL). J Bone Miner Res 35:883\u2013893. https:\/\/doi.org\/10.1002\/jbmr.3958","journal-title":"J Bone Miner Res"},{"key":"1082_CR83","unstructured":"Gunnarsson J, Lauppe R, Csomor P, et al (2020) Indirect comparison of treatments for secondary hyperparathyroidism through a network meta-analysis (abstract P0358). J Am Soc Nephrol 31:159 https:\/\/www.asn-online.org\/education\/kidneyweek\/2020\/program-abstract.aspx?controlId=3444774 Accessed 20 May 2021"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-021-01082-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:09Z","timestamp":1777564509000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/5\/1405\/8325832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s40620-021-01082-2","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Markus Ketteler has received lecture fees and consulting honoraria from Amgen, Kyowa Kirin, Ono Pharmaceuticals, Vifor Fresenius Medical Care Renal Pharma and Vifor Pharma. Patrice Amb\u00fchl has no financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}